Cover Image
市場調查報告書

代謝型麩胺酸受體5 (mGluR5/GRM5/GPRC1E/MGLUR5):開發中產品分析

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 363126
出版日期 內容資訊 英文 88 Pages
訂單完成後即時交付
價格
Back to Top
代謝型麩胺酸受體5 (mGluR5/GRM5/GPRC1E/MGLUR5):開發中產品分析 Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H2 2016
出版日期: 2016年10月12日 內容資訊: 英文 88 Pages
簡介

本報告提供全球各國的代謝型麩胺酸受體5 (mGluR5/GRM5/GPRC1E/MGLUR5) 治療用的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

目錄

  • 簡介
    • 分析範圍
  • 代謝型麩胺酸受體5 (mGluR5/GRM5/GPRC1E/MGLUR5)的概要
  • 治療藥的開發
    • 臨床實驗的各階段
    • 各治療領域
    • 各症狀
  • 開發中產品的概要
    • 後期階段的產品
    • 初期階段的產品
  • 各企業開發中的治療藥
  • 各大學/研究機關開發中的治療藥
  • 治療藥的評估
    • 單劑治療藥/並用治療藥的情況
    • 各作用機制
    • 各投藥法
    • 各分子類型
  • 開發治療藥的企業
    • Addex Therapeutics Ltd
    • Confluence Pharmaceuticals LLC
    • Eisai
    • Eli Lilly and Company
    • Heptares Therapeutics Limited
    • Hua Medicine (Shanghai) Ltd.
    • Johnson & Johnson
    • Medgenics, Inc.
    • Merz Pharma GmbH & Co. KgaA
    • Novartis AG
    • 大日本住友製藥
  • 藥物簡介
    • acamprosate calcium
      • 產品概要
      • 作用機制
      • 研究開發 (R&D)的發展情形
    • alloswitch-1
    • dipraglurant ER (控制放出)
    • dipraglurant IR (即時放出)
    • DSR-98776
    • fasoracetam
    • GET-73
    • HTL-14242
    • JNJ-46778212
    • LSN-2463359
    • LSN-2814617
    • mavoglurant
    • MRZ-8676
    • 癡呆症的代謝型麩胺酸受體5 (mGlu5) 活性化用小分子
    • 疼痛的mGlu5較量用小分子
    • 神經疾病的mGluR、mGluR6較量用小分子
    • 中樞神經系統 (CNS) 疾病的mGluR5較量用小分子
    • 運動功能障礙的mGluR5較量用小分子
    • 思覺失調症的mGluR5標的小分子
    • VU-0092273
    • VU-0431316
    • VU-0463841
    • VU-0467558
  • 開發暫停的產品
  • 開發中止的產品
  • 值得注意的最新趨勢、新聞稿 (共15件)
  • 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0584TDB

Summary

Global Markets Direct's, 'Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H2 2016', provides in depth analysis on Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted pipeline therapeutics.

The report provides comprehensive information on the Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5)
  • The report reviews Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) Overview
  • Therapeutics Development
    • Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Products under Development by Stage of Development
    • Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Products under Development by Therapy Area
    • Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Products under Development by Indication
  • Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Products under Development by Companies
  • Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Products under Development by Universities/Institutes
  • Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • Bristol-Myers Squibb Company
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • Heptares Therapeutics Limited
    • Hua Medicine (Shanghai) Ltd.
    • Johnson & Johnson
    • Medgenics, Inc.
    • Merz Pharma GmbH & Co. KgaA
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Toray Industries, Inc.
  • Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Drug Profiles
    • alloswitch-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-952048 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-955829 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dipraglurant ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dipraglurant IR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DSR-98776 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fasoracetam - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GET-73 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HTL-14242 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-46778212 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LSN-2463359 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LSN-2814617 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • remeglurant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize Metabotropic Glutamate Receptor 5 for Cognitive Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize mGlu5 for Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize mGluR5 for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize mGluR5 for Schizophrenia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize mGluR5 for Anxiety - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize mGluR5 for Dyskinesia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VU-0092273 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VU-0431316 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VU-0463841 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VU-0467558 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Dormant Projects
  • Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Discontinued Products
  • Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Featured News & Press Releases
    • Jun 17, 2016: Medgenics Announces Enrollment of First Patient in Phase 2/3 Clinical Trial of NFC-1 in Adolescents With mGluR Mutation Positive ADHD
    • Jun 02, 2016: Addex Dipraglurant Positive Phase 2 Data in PD-LID Published in Leading Peer Reviewed Journal of the Movement Disorder Society
    • Apr 11, 2016: Addex Reports Positive Results of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers
    • Mar 15, 2016: Addex Reports Successful Completion of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers
    • Jan 11, 2016: Addex Dipraglurant Shows Highly Statistically Significant Anti-Dyskinetic Effects Following Additional Analysis of Data from the PD-LID Phase II Proof of Concept
    • Jan 04, 2016: Addex' Dipraglurant Receives Orphan Drug Designation from the FDA for Levodopa-Induced Dyskinesia Associated with Parkinson's Disease
    • Dec 17, 2015: Addex Reports Statistically Significant Positive Interim Data for Dipraglurant in Healthy Volunteer mGlu5 Receptor Occupancy Trial
    • Aug 14, 2015: Addex Dipraglurant Demonstrates Anxiolytic- and Antidepressant-like Activity in Multiple Preclinical Models Relevant for Non-Motor Symptoms in Parkinson's Disease
    • Jul 22, 2015: Addex Dipraglurant Dosed in First Subject in Receptor Occupancy Study in Collaboration with Johns Hopkins University and with Funding from The Michael J. Fox Foundation
    • Feb 23, 2015: Addex Initiates Dipraglurant Receptor Occupancy Clinical Study in Collaboration with Johns Hopkins University with Funding from The Michael J. Fox Foundation
    • Jan 19, 2015: Addex and Dystonia Medical Research Foundation Announce Partnership to Explore the Therapeutic use of Dipraglurant in the Treatment of Dystonia
    • Sep 04, 2013: Chronic treatment with Addex Dipraglurant Rescues Impairment of Long-Term Synaptic Plasticity in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1
    • May 01, 2013: Addex's Dipragluant Demonstrates Dose-dependent mGlu5 Receptor Occupancy In Non-human Primate PET Study
    • Apr 22, 2013: Addex Obtains European Composition Of Matter Patent Covering Dipraglurant And Other mGlu5 Negative Allosteric Modulators
    • Apr 18, 2013: Addex's Dipraglurant Normalizes Striatal Cholinergic Dysfunction In Validated Preclinical Model Of Primary Generalized Torsion Dystonia 1
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Addex Therapeutics Ltd, H2 2016
  • Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Pipeline by Eisai Co., Ltd., H2 2016
  • Pipeline by Eli Lilly and Company, H2 2016
  • Pipeline by Heptares Therapeutics Limited, H2 2016
  • Pipeline by Hua Medicine (Shanghai) Ltd., H2 2016
  • Pipeline by Johnson & Johnson, H2 2016
  • Pipeline by Medgenics, Inc., H2 2016
  • Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2016
  • Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
  • Pipeline by Toray Industries, Inc., H2 2016
  • Dormant Projects, H2 2016
  • Dormant Projects (Contd..1), H2 2016
  • Dormant Projects (Contd..2), H2 2016
  • Dormant Projects (Contd..3), H2 2016
  • Discontinued Products, H2 2016
  • Discontinued Products (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top